739.20 -13.60 (-1.81%)
NSE Oct 29, 2020 12:39 PM
Volume: 75,109

Jubilant Life Sciences Ltd.    
07 Sep 2020
Prabhudas Lilladhar
We reduce earnings estimate of JUBILANT by 23%17.5%11.6% for FY21/22/23E due to weak and inconsistent performance of its Pharmaceutical segment (65% revenue and 78% EBITDA contribution in FY20) whose key contributors Radio pharma and Allergy are currently witnessing lower volumes caused by pandemic in US. Radiopharma being a hospital driven...
Jubilant Life Sciences Ltd. is trading above it's 200 day SMA of 595.1
More from Jubilant Life Sciences Ltd.